Previous 10 | Next 10 |
ESSA Pharma (EPIX) has priced its public offering of ~4.8M common shares at $27.00/share, for gross proceeds of ~$130.4M.Underwriters' over-allotment is an additional ~724.6K shares.Net proceeds will be used for pre-clinical and clinical activities, manufacturing and controls, R&D, workin...
ESSA Pharma (EPIX) down 0.76% after-market, as it commences an underwritten public offering of up to $100M of its common shares.ESSA intends to use the net proceeds for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as ...
ESSA Pharma (EPIX) has climbed ~46.9% after the company disclosed the initial Phase 1 data for EPI-7386 for the treatment of patients with metastatic castration-resistant prostate cancer.An oral, small molecule that selectively inhibits the androgen receptor's N-terminal domain...
Gainers: ESSA Pharma (EPIX) +47%. Ayala Pharmaceuticals (AYLA) +45%. GenMark Diagnostics (GNMK) +27%. ADiTx Therapeutics (ADTX) +27%. Celsion (CLSN) +26%.Losers: Tilray (TLRY) -39%. Anchiano Therapeutics (ANCN) -35%. Zynerba Pharmaceuticals (ZYNE) -28%. Pulmatrix (PULM) -26%. Aphria (APHA) -2...
Gainers: RCM Technologies (RCMT) +85%.Ayala Pharmaceuticals (AYLA) +60%.ESSA Pharma (EPIX) +45%.GenMark Diagnostics (GNMK) +29%.Castor Maritime (CTRM) +28%.Borqs Technologies (BRQS) +26%.SOS Limited (SOS) +25%.Lyra Therapeutics (LYRA) +25%.Inpixon (INPX) +25%.Quotient Technology (QUOT) +...
ESSA Pharma Presents Favorable Initial Phase 1 Clinical Pharmacology Data of EPI-7386 for Advanced Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium PR Newswire VANCOUVER, BC and HOUSTON , Feb. 11, 2021 /PRNewswire/ - ESSA Pharma I...
ESSA Pharma (EPIX): Q4 GAAP EPS of -$0.20.Press Release For further details see: ESSA Pharma reports Q4 results
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2020 Canada NewsWire VANCOUVER, BC and HOUSTON , Feb. 11, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stag...
On January 13, ESSA announced a collaboration agreement with Janssen to evaluate ESSA's EPI-7386 in combo with Janssen's apalutamide and in combo with abiraterone acetate plus prednisone in patients with mCRPC. EPI-7386 is a novel approach to treat prostate cancer by targeting the N-t...
ESSA Pharma (EPIX) has entered into a clinical collaboration and supply agreement with Johnson & Johnson's (JNJ) company Janssen, to evaluate two combination with Essa's androgen receptor inhibitor EPI-7386 in patients with metastatic castration-resistant prostate cancer ((mCRPC...
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...